Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?
Economy

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Last updated: April 23, 2025 6:12 pm
Share
Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?
SHARE

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that has been in the spotlight recently as one of the cheap NASDAQ stocks to buy according to hedge funds. With a forward P/E ratio of 13.24 and 74 hedge fund holders, Gilead is making waves in the industry.

In a recent interview on CNBC, Dan Ives, Head of Global Tech Research at Wedbush Securities, discussed the current state of the tech sector, highlighting the potential for major volatility ahead. The uncertainty in the tech industry has been exacerbated by escalating tariffs on China, reaching as high as 125%. This has forced companies to rethink their supply chains and has resulted in a noticeable pause in tech spending.

Despite the challenges, Ives has not downgraded tech stocks, emphasizing the potential for clear winners to emerge from the current turmoil. He predicts that Street estimates are likely to see earnings cuts of about 10% across internet and big tech companies, reflecting the broader pullback in spending and ongoing volatility.

Gilead Sciences has seen success in its HIV franchise, with sales reaching $19.6 billion in 2024. Key products like Biktarvy and Descovy have contributed to this growth, solidifying Gilead’s position in the market. While the company expects some temporary challenges in 2025 due to Medicare Part D reform, the underlying HIV business remains strong.

In a recent investor letter, ClearBridge Value Strategy praised Gilead’s performance, citing strong fourth-quarter earnings growth and positive reception to its new treatments. Overall, Gilead ranks 9th on the list of cheap NASDAQ stocks to buy according to hedge funds.

See also  Dr. Oz and Dr. Bhattacharya will sell stock to limit conflicts : Shots

While Gilead shows promise, there are other opportunities in the market, particularly in AI stocks. These stocks have the potential to deliver high returns in a shorter time frame. If you’re looking for an AI stock with significant growth potential, consider exploring the cheapest AI stock highlighted in our report.

In conclusion, Gilead Sciences is positioned as a strong contender in the biopharmaceutical industry, with a solid track record and promising future prospects. However, investors should also consider exploring opportunities in AI stocks for potentially higher returns. Stay informed and make informed investment decisions based on the latest market trends and opportunities.

TAGGED:BuyCheapfundsGILDGileadhedgeNasdaqSciencesStock
Share This Article
Twitter Email Copy Link Print
Previous Article Can climate science attribute economic damage to major polluters? Can climate science attribute economic damage to major polluters?
Next Article How Legal Aid’s pro-crime push puts all of us in danger How Legal Aid’s pro-crime push puts all of us in danger
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Palmer Harding Spring 2026 Ready-to-Wear Collection

The world of fashion is often celebrated for its iconic status—filled with figures that inspire…

October 1, 2025

Retirement in America is a disaster for many. Is there hope?

Retirement can be a time of relaxation and enjoyment, a time to reap the rewards…

October 5, 2024

Trump Warns Europe on Immigration: ‘Horrible Invasion’ is ‘Killing’ the Continent (Video) |

Photo by Jordan Conradson has reported on President Trump's arrival in Turnberry, Scotland, where he…

July 26, 2025

AI Superintelligence Startup Promises New Drug Discoveries

Artificial Intelligence and Robotics Revolutionizing Drug Discovery and Scientific Research In the ever-evolving landscape of…

March 12, 2025

Epic Games asks judge to force Apple to approve Fortnite

Epic Games Continues Legal Battle with Apple Over Fortnite After a recent court ruling in…

May 17, 2025

You Might Also Like

Is there an AI bubble? Financial institutions sound a warning
Economy

Is there an AI bubble? Financial institutions sound a warning

October 10, 2025
Mark Wahlberg in Contract to Buy  Million Mansion in South Florida
Entertainment

Mark Wahlberg in Contract to Buy $47 Million Mansion in South Florida

October 10, 2025
AMD Stock Is Soaring on an OpenAI Deal, But Analysts Still Think It Can Climb 35% From Here
Economy

AMD Stock Is Soaring on an OpenAI Deal, But Analysts Still Think It Can Climb 35% From Here

October 10, 2025
Why Confluent Stock Popped Today
Economy

Why Confluent Stock Popped Today

October 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?